tipifarnib has been researched along with bortezomib in 9 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 6,868 | 860 | 4,753 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Blijlevens, N; de Witte, T; Langemeijer, S; Muus, P; van Bijnen, S | 1 |
2 review(s) available for tipifarnib and bortezomib
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
2 trial(s) available for tipifarnib and bortezomib
| Article | Year |
|---|---|
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Quinolones; Treatment Outcome | 2021 |
5 other study(ies) available for tipifarnib and bortezomib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |